An updated assessment of 43,110 patients enrolled in the Childhood Cancer Research Network: A Children's Oncology Group report.
cancer registry
childhood cancer
clinical trial
epidemiology
research participation
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
15 07 2022
15 07 2022
Historique:
revised:
04
04
2022
received:
06
12
2021
accepted:
18
04
2022
pubmed:
29
4
2022
medline:
24
6
2022
entrez:
28
4
2022
Statut:
ppublish
Résumé
The Childhood Cancer Research Network (CCRN) was established by the Children's Oncology Group (COG) as a resource for epidemiologic studies of childhood cancer. The objective of this study was to evaluate the representativeness of CCRN and identify factors associated with enrollment. The number of US childhood patients with cancer diagnosed <20 years of age enrolled in CCRN (2008-2015) was compared to expected counts, calculated from Surveillance, Epidemiology, and End Results incidence rates and US Census population estimates. Observed-to-expected ratios and corresponding 95% confidence intervals (CI) were estimated across sex, race, diagnosis age, calendar year, and cancer diagnosis groups. Multivariable linear regression models were generated to evaluate the association between open COG phase 3 therapeutic trials and CCRN enrollment rates. The 43,110 cases enrolled in CCRN represented 36% of the expected childhood cancers diagnosed from 2008 to 2015 (N = 120,118). CCRN enrollment ratios [95% CI] were highest among males (0.38 [95% CI, 0.37-0.38]), non-Hispanics (0.35 [95% CI, 0.35-0.36]), and those diagnosed from 1 to 4 years of age (0.50 [95% CI, 0.50-51]). Enrollment ratios varied by diagnosis group, with leukemia, myeloproliferative diseases, myelodysplastic diseases (0.55 [95% CI, 0.54-0.55]), and renal tumors (0.55 [95% CI, 0.53-0.58]) having the highest enrollment. After adjusting for year of diagnosis and cancer diagnosis, there was a 3.1% [95% CI, 0.6-5.6%] increase in CCRN enrollment during windows of open COG therapeutic trials. Despite enrolling only 36% of newly diagnosed cases, CCRN remains a valuable resource for investigators conducting childhood cancer etiology and survivorship research. The results of this study may inform efforts to improve enrollment on current and future COG nontherapeutic registry protocols.
Sections du résumé
BACKGROUND
The Childhood Cancer Research Network (CCRN) was established by the Children's Oncology Group (COG) as a resource for epidemiologic studies of childhood cancer. The objective of this study was to evaluate the representativeness of CCRN and identify factors associated with enrollment.
METHOD
The number of US childhood patients with cancer diagnosed <20 years of age enrolled in CCRN (2008-2015) was compared to expected counts, calculated from Surveillance, Epidemiology, and End Results incidence rates and US Census population estimates. Observed-to-expected ratios and corresponding 95% confidence intervals (CI) were estimated across sex, race, diagnosis age, calendar year, and cancer diagnosis groups. Multivariable linear regression models were generated to evaluate the association between open COG phase 3 therapeutic trials and CCRN enrollment rates.
RESULT
The 43,110 cases enrolled in CCRN represented 36% of the expected childhood cancers diagnosed from 2008 to 2015 (N = 120,118). CCRN enrollment ratios [95% CI] were highest among males (0.38 [95% CI, 0.37-0.38]), non-Hispanics (0.35 [95% CI, 0.35-0.36]), and those diagnosed from 1 to 4 years of age (0.50 [95% CI, 0.50-51]). Enrollment ratios varied by diagnosis group, with leukemia, myeloproliferative diseases, myelodysplastic diseases (0.55 [95% CI, 0.54-0.55]), and renal tumors (0.55 [95% CI, 0.53-0.58]) having the highest enrollment. After adjusting for year of diagnosis and cancer diagnosis, there was a 3.1% [95% CI, 0.6-5.6%] increase in CCRN enrollment during windows of open COG therapeutic trials.
CONCLUSIONS
Despite enrolling only 36% of newly diagnosed cases, CCRN remains a valuable resource for investigators conducting childhood cancer etiology and survivorship research. The results of this study may inform efforts to improve enrollment on current and future COG nontherapeutic registry protocols.
Identifiants
pubmed: 35482017
doi: 10.1002/cncr.34248
pmc: PMC9233076
mid: NIHMS1804280
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
2760-2767Subventions
Organisme : NCI NIH HHS
ID : R01 CA266105
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA098413
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA098543
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180899
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180886
Pays : United States
Informations de copyright
© 2022 American Cancer Society.
Références
Cancer Epidemiol. 2019 Aug;61:165-171
pubmed: 31279991
CA Cancer J Clin. 2014 Mar-Apr;64(2):83-103
pubmed: 24488779
Cancer. 2018 Oct 1;124(19):3900-3908
pubmed: 30291793
PLoS One. 2020 Apr 23;15(4):e0230824
pubmed: 32324751
CA Cancer J Clin. 1990 Nov-Dec;40(6):355-67
pubmed: 2121321
Genes Chromosomes Cancer. 2017 Jul;56(7):548-558
pubmed: 28295819
Cancer Causes Control. 2016 Oct;27(10):1209-18
pubmed: 27541142
Cancer. 2008 Jan 15;112(2):228-42
pubmed: 18008363
Cancer. 2021 Oct 1;127(19):3651-3663
pubmed: 34151418
Cancer Epidemiol Biomarkers Prev. 2004 Oct;13(10):1552-4
pubmed: 15466968
Haematologica. 2020 Sep 10;105(11):2524-2539
pubmed: 33054110
Int J Epidemiol. 2021 Mar 3;50(1):116-127
pubmed: 33221912
Cancer Cell. 2017 Jun 12;31(6):737-754.e6
pubmed: 28609654
Br J Cancer. 2018 Jan;118(1):121-126
pubmed: 29065103
J Clin Oncol. 2010 May 20;28(15):2625-34
pubmed: 20404250
Cancer Epidemiol Biomarkers Prev. 2006 Jul;15(7):1241-2
pubmed: 16835317
N Engl J Med. 2006 Oct 12;355(15):1572-82
pubmed: 17035650
Cancer. 2008 Jan 15;112(2):416-32
pubmed: 18074355
Lancet Oncol. 2018 Dec;19(12):1590-1601
pubmed: 30416076
Cancer. 2014 Oct 1;120(19):3007-15
pubmed: 24889136
J Adolesc Young Adult Oncol. 2019 Jun;8(3):227-235
pubmed: 30676208
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Br J Cancer. 2018 Oct;119(7):864-872
pubmed: 30287918
JCO Precis Oncol. 2020 Oct 2;4:
pubmed: 33163847